‘This Was Always Going To Be A Multi-Year Journey’ – Sandoz’s CEO On The Road Ahead
Chief Executive Richard Saynor Discusses Sandoz’s Future Strategy
In the first instalment of a three-part interview with Richard Saynor, the Sandoz CEO talks about the aftermath of the company’s spinoff from former parent Novartis and the work still left to do; the increasing prominence of biosimilars for Sandoz; the firm’s investments in manufacturing; thoughts on the potential for significant M&A; and future opportunities for the industry leader.
